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Abstract
Mycobacterium avium, subspecies paratuberculosis (MAP) causes a chronic disease of the intestines in dairy cows
and a wide range of other animals, including nonhuman primates, called Johne’s ("Yo-knee’s”) disease. MAP has
been consistently identified by a variety of techniques in humans with Crohn’s disease. The research investigating
the presence of MAP in patients with Crohn’s disease has often identified MAP in the “negative” ulcerative colitis
controls as well, suggesting that ulcerative colitis is also caused by MAP. Like other infectious diseases, dose, route
of infection, age, sex and genes influence whether an individual infected with MAP develops ulcerative colitis or
Crohn’s disease. The apparently opposite role of smoking, increasing the risk of Crohn’s disease while decreasing
the risk of ulcerative colitis, is explained by a more careful review of the literature that reveals smoking causes an
increase in both diseases but switches the phenotype from ulcerative colitis to Crohn’s disease. MAP as the sole
etiologic agent of both ulcerative colitis and Crohn’s disease explains their common epidemiology, geographic
distribution and familial and sporadic clusters, providing a unified hypothesis for the prevention and cure of the no
longer “idiopathic” inflammatory bowel diseases.
Introduction
Ulcerative colitis and Crohn’s disease are chronic dis-
eases of the gastrointestinal tract that together are
usually referred to as idiopathic inflammatory bowel dis-
e a s e( I I B D ) .T h ew o r d“idiopathic” means “of unknown
cause,” but the currently accepted theory of the cause of
these diseases postulates a nebulous combination of
immune dysfunction, “dysbiosis,” [1] and otherwise nor-
mal constituents of the commensal extracellular luminal
gut bacteria [2] leaking through an abnormally perme-
able mucosal layer [3] in genetically predisposed indivi-
duals [4].
The main alternative theory of Crohn’s disease causa-
tion is infection with a facultative intracellular bacter-
ium, Mycobacterium avium, subspecies paratuberculosis
(MAP) [5-8]. MAP causes a chronic disease of the intes-
tines [9,10] in a variety of animals [11-16], including
nonhuman primates [17], that shares some histologic
(i.e., microscopic) similarities to the changes found in
Crohn’s disease.
This commentary proposes that ulcerative colitis is also
caused by MAP. The epidemiology, geographic distribu-
tion [18] and clusters (both sporadic and familial) of
ulcerative colitis and Crohn’s disease are consistent with
MAP as the single etiologic agent of both diseases. Like
other infectious diseases [19], a variety of factors includ-
ing dose, route of infection, age, sex and genes influences
whether an individual infected with MAP develops
ulcerative colitis or Crohn’s disease.
Discussion
Crohn’s disease in unrelated individuals is an infectious
disease; it is caused by a microorganism transmitted in
water by the fecal-oral route
Let’s begin in the middle of the story. What causes
Crohn’s disease, and how are ulcerative colitis and
Crohn’s disease related to one another? In 2001, Van
Kruiningen and Freda [20] published their study of a
“clustering of Crohn’s disease in Mankato, Minnesota,”
that described 7 unrelated individuals with Crohn’s
disease in the city of Mankato, all members of the
Mankato West High School class of 1980. The circum-
stances of the development of their Crohn’s disease led
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of Crohn’s disease were caused by
environmental transmission, transmission of a mod-
estly contagious microbial agent via a fecal-oral
route...related to bacterial surface water pollution...
(Crohn’s disease) may have been contracted via bath-
ing or swimming in contaminated waters, via con-
tamination of fresh vegetable crops, or via surface
water contamination of wells during flooding [20].
Fecal-oral transmission means that a microorganism
present in the feces of an animal contaminates the
food or water that a person swallows. This one study
c o n c l u d e dt h a tC r o h n ’s disease in unrelated individuals
is an infectious disease; that is, it is caused by a micro-
organism, found in animal feces, that contaminates
water.
Crohn’s disease in families, in genetically related
individuals, is also an infectious disease
Genetically related individuals, families who have sev-
eral members with Crohn’s disease, also develop
Crohn’s disease because they are infected with the cau-
sative microorganism. In 1993, Van Kruiningen and
colleagues published a “Study of Crohn’s disease in
Two French Families.” [21] In the first family, the
father developed Crohn’s disease in 1970. In 1974,
within several months of each other, 2 of their 4 chil-
dren developed Crohn’s disease. In 1982 and 1983, the
other two children developed Crohn’s disease. Finally,
in 1988, the mother developed Crohn’sd i s e a s e .I nt h e
second family, 7 of the 11 children developed Crohn’s
disease, again in a pattern (first 4 of the children
within 10 months of each other, then 6 years later
another child, then 6 years after that, 2 more siblings)
that led the authors of this study to conclude that “an
enteric pathogen” caused these families to develop
Crohn’sd i s e a s e :
The uniformity of ileal and cecal disease in family 1
is akin to that which might be expected had a uni-
form dose of an enteric pathogen been given to a
genetically uniform group of experimental subjects,
e.g., a litter of mice or piglets [21].
The conclusions that can be drawn from these two
studies are that genetically unrelated people develop
Crohn’s disease because they have been infected with
the causative microorganism, and genetically related
people also develop Crohn’s disease because they
have been infected with the causative microorganism.
Sporadic Crohn’sd i s e a s e ,C r o h n ’s disease in genetically
unrelated individuals, is the same disease as familial Crohn’s
disease, Crohn’s disease in genetically related individuals
We have thus far determined that Crohn’sd i s e a s e ,
whether in related or unrelated individuals, is an infec-
tious disease, meaning that people develop Crohn’sd i s -
ease because they have been infected with the causative
microorganism. But is sporadic Crohn’sd i s e a s et h e
same kind of disease as familial Crohn’sd i s e a s e ?I st h e
infectious microorganism that causes unrelated people
to develop Crohn’s disease the same microorganism that
causes families to develop Crohn’sd i s e a s e ?S t u d i e so f
families with Crohn’s disease have concluded that there
is no essential difference between the pathology of
Crohn’s disease in families with the disease and in unre-
lated individuals with the disease. Since there are no
essential differences in the pathology of sporadic versus
familial Crohn’s disease [22-25], the organism that
causes them must also be the same.
How is ulcerative colitis related to Crohn’s disease? The
same infectious microorganism that causes Crohn’s
disease sometimes causes ulcerative colitis instead
The studies of sporadic and familial clusters of Crohn’s
disease conclude that Crohn’s disease is caused by an
infectious microorganism, and that, whether sporadic or
familial, Crohn’s disease is the same disease. How, then,
is ulcerative colitis related to Crohn’s disease? Let’s
return to those “two French families” [21], where a total
of 13 individuals developed Crohn’s disease. In the sec-
ond of these families, in which 7 of the 11 children
developed Crohn’s disease, one affected child “presented
initially with diffuse mucosal colitis and may have had
u l c e r a t i v ec o l i t i sa sw e l la sC r o h n ’sd i s e a s e . ” [21] The
same “enteric pathogen,” the same “infectious microor-
ganism” that caused the 13 individuals in these two
families to develop Crohn’s disease caused one of those
13 individuals to also develop ulcerative colitis.
The same microorganism that causes the rare patient
to develop both Crohn’s disease and ulcerative colitis
[26-29] usually causes some individuals to develop one
disease or the other. Numerous studies of “mixed”
families [30-34], where some individuals in a family
develop ulcerative colitis and others develop Crohn’s dis-
ease, are usually used to illustrate the idea that Crohn’s
disease and ulcerative colitis are genetic diseases, that
some combination of genes causes both diseases. If, how-
ever, Crohn’s disease is an infectious disease, these same
studies of “mixed” families can just as easily illustrate the
idea that if an infectious microorganism causes Crohn’s
disease, that same infectious microorganism sometimes
causes ulcerative colitis instead [30-34].
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related individuals to get ulcerative colitis and others to
get Crohn’s disease, and if sporadic Crohn’s disease
(Crohn’s disease in genetically unrelated individuals) is
the same disease as familial Crohn’sd i s e a s e( C r o h n ’s
disease in genetically related individuals), then some-
times unrelated people will get ulcerative colitis rather
than Crohn’s disease when infected with the same
microorganism. This is illustrated by the first of the two
French families, where both the (genetically unrelated)
mother and the father developed Crohn’s disease [21],
as well as the studies of unrelated spouses who both
develop IBD: in some cases both spouses develop
Crohn’s disease [35-37], in some cases one spouse devel-
ops Crohn’s disease and the other ulcerative colitis
[38-40], and in some cases both spouses develop ulcera-
tive colitis [38-41].
Unmarried and unrelated individuals living together
also sometimes develop ulcerative colitis rather than
Crohn’s disease when infected with the same microor-
ganism. In one of these nonfamilial or sporadic clusters,
Aisenberg and Janowitz [42] describe 3 friends who
shared living quarters in college. Several years after they
left school, 2 of the friends developed Crohn’s disease,
and 1 developed ulcerative colitis.
T h ei d e at h a tu l c e r a t i v ec o l i t i sa n dC r o h n ’s disease
have the same etiology is supported by consideration of
the general epidemiology of these two disorders:
The significant linear regression between the inci-
dence of Crohn’s disease and ulcerative colitis from
different countries and a similar relationship
between the mortalities from both diseases could
mean that the two diseases share a common factor
in their etiology [43].
All studies (of the populations affected by IBD) thus
far have failed to show that the population which
develops Crohn’s disease differs in any important fea-
ture from that which develops ulcerative colitis [44].
Crohn’s disease and ulcerative colitis have similar
demographic features. They...occur in the same
places and at similar times. Where Crohn’s disease is
common, so is ulcerative colitis [45].
Which specific infectious microorganism is found in
patients with Crohn’s disease ...and ulcerative colitis?
MAP
MAP is an organism found in animal feces. It infects
and causes clinical disease, called Johne’s( ‘Yo-knees’)
disease, in a wide variety of animal species. Several
meta-analyses and reviews of the literature have con-
cluded that the MAP organism is consistently associated
with Crohn’s disease [46-48]:
...the MAP Crohn’s disease phenomenon has fulfilled
at least four (strength of association, consistency of
effect, temporality and biological plausibility) of the
six epidemiological causal criteria outlined by Hill...
the current epidemiological evidence strongly sup-
ports the conjecture that Crohn’s disease is caused
by MAP [46].
There is an association between MAP and (Crohn’s
disease), across many sites, by many investigators,
and controlling for a number of factors [48].
...our meta-analysis showed an association bet-
ween MAP and Crohn’s disease that is robust and
specific [49].
The studies attempting to identify the MAP organism
in Crohn’s disease by a variety of techniques have often
used ulcerative colitis as the “negative” control, under
the assumption that MAP may cause Crohn’sd i s e a s e ,
but not ulcerative colitis [47,48]. When MAP is identi-
fied in both Crohn’s disease and ulcerative colitis,
researchers conclude that MAP causes neither disease.
If, however, the current body of research is looked at
from the point of view that MAP might cause ulcerative
colitis as well as Crohn’s disease, there is evidence to
support this alternative position.
Like the organism that causes tuberculosis, Mycobac-
terium tuberculosis, that infects one-third of the world’s
population [50] as estimated by positive tuberculin skin
testing [19], serum antibodies to various MAP antigens
are found in a third of the population in countries with
a high incidence of ulcerative colitis and Crohn’s disease
[51] and in patients with both diseases [51-53]. MAP
can be identified by IS900 PCR (polymerase chain reac-
tion) in the tissues [54-58] and cultured from the blood-
streams [59] of patients with ulcerative colitis as well as
patients with Crohn’s disease.
For a pathologist such as the author, the most convin-
cing evidence of causation is direct visualization: can
the organism be seen under the (light) microscope? The
evidence from direct visualization is actually the stron-
gest support for the idea that MAP causes ulcerative
c o l i t i sa sw e l la sC r o h n ’s disease: MAP can be directly
visualized in patients with both diseases [60,61]. In the
single study that directly visualized MAC (Mycobacter-
ium avium complex) organisms (of which MAP is one)
in almost 60% of Crohn’s tissues using traditional acid
fast stains [60], MAC organisms were also seen in 40%
(2 of the 5) of the ulcerative colitis tissues. However,
these researchers went so far as to reclassify their
ulcerative colitis patients as having Crohn’s disease,
rather than concluding that MAC organisms can be
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tissues:
...the observation of positive results in a few controls
requires further clarification ...2 of the 5 control sub-
jects with positive results had ileal disease but an
assigned diagnosis of UC (ulcerative colitis); if these
patients instead were classified as Crohn’sd i s e a s e ,
the Odds Ratio would increase from 8.6 to 17.1 [60].
If the data are accepted that MAP is present in both
ulcerative colitis and Crohn’s disease tissues, the conclu-
sion can be drawn that MAP causes both diseases. Why,
then, do some patients develop ulcerative colitis rather
than Crohn’s disease when infected with the same
microorganism?
When infected with MAP, why do some individuals
develop ulcerative colitis rather than Crohn’s disease?
The usual influences of dose, route, age, sex and genes
on the clinical expression of an infection
Like any other pathogenic (disease-causing) microorgan-
ism, a variety of factors influences the phenotype, the
clinical expression of MAP infection; whether an indivi-
dual develops one disease caused by MAP or another.
Not everyone infected by a pathogenic microorganism
develops a disease caused by that organism. “Infection”
means the “multiplication of the organism in or on the
host.” [19] In contrast, “disease represents a clinically
apparent response of the host to infection.” [19]
A review of the literature suggests that five factors influ-
ence whether an individual develops ulcerative colitis or
Crohn’s disease when infected with MAP:
1 )T h ed o s eo ft h eM A Po r g a n i s m ,o rh o wm a n y
organisms infect an individual. For a given age, a
small dose of MAP causes ulcerative colitis, while a
large dose of MAP causes Crohn’s disease.
2) The route of infection. The literature suggests
that routes of infection that increase the concentra-
tion of MAP increase the risk of developing Crohn’s
disease rather than ulcerative colitis. The two routes
of infection that potentially concentrate MAP are
aerosolized water from rivers and other bodies of
water contaminated with MAP, and MAP present in
hyperosmolar milk rather than hypoosmolar water.
3) The age at which an individual is infected. It takes
a smaller dose of MAP to cause either ulcerative
colitis or Crohn’s disease in a child as compared to
an adult.
4) Specific genes that control how an individual pro-
cesses intracellular bacteria, and specifically myco-
bacteria. Individuals with these genes have a slighter
greater tendency to develop Crohn’s disease rather
than ulcerative colitis, when infected with the MAP
organism.
5) Whether an individual is male or female. Infant
males and adult females seem to have a greater
chance of developing Crohn’s disease rather than
ulcerative colitis when infected with MAP.
The interactive influences of age and dose: when infected
with a small dose of MAP, adults develop ulcerative
colitis relatively soon after being infected, while children
develop Crohn’s disease after a long latency period
An examination of another family with both diseases
suggests why some people get ulcerative colitis and
others get Crohn’s disease when infected with the same
microorganism. This family had been living in a section
of Germany with water that “was poorly controlled
hygienically.” [62] The mother, the adult, developed
ulcerative colitis only 6 months after living in the area.
Her two children developed Crohn’s disease, one 4 years
after living in the area and the other 5 years after.
This pattern of development, first of ulcerative colitis,
then several years later of Crohn’s disease, is illustrated
occasionally at the individual level in patients who first
develop ulcerative colitis, and then approximately
10 years later develop Crohn’s disease [27]. More com-
monly, in high incidence countries, the incidence of
ulcerative colitis first increases, followed several years
later by Crohn’s disease [63-65]. At the population level,
immigrants from low to high prevalence IBD countries
first develop ulcerative colitis [66], then again after
approximately a decade begin developing Crohn’sd i s -
ease [67-70]. Adult and child immigrants from low to
high prevalence IBD countries are infected at the same
time, but the adults develop ulcerative colitis relatively
soon after being infected, while the children develop
Crohn’s disease approximately 5 to 15 years after infec-
tion. The latency period between infection with MAP
and the development of Crohn’s disease is consistent
with the literature on Johne’s disease, where animals are
infected as young animals but don’t develop the clinical
disease until they are adults [71].
As countries become westernized, meaning specifically
the introduction of MAP-contaminated beef and dairy
foods and the corresponding environmental pollution by
MAP-infested beef and dairy cattle feces, their popula-
tions first develop ulcerative colitis and then again after
a delay of several years develop Crohn’s disease:
As societies become more “westernized” or indus-
trialized...ulcerative colitis emerges, but the incidence
of Crohn’s disease remains low. Over time, Crohn’s
disease emerges, and its incidence ultimately
matches that of ulcerative colitis [69].
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colitis) has changed over the past 50 years, with
early reports in the mid-20
th century describing a
predominance of UC cases in the United States and
Western Europe. A gradual rise in CD cases in the
1960’s through the 1990’s resulted in CD incidence
surpassing UC incidence in most westernized coun-
tries. Studies from Japan recapitulate the US experi-
ence, with a predominance of UC cases early and a
rise in CD approximately 1 decade later [67].
For a given age, infection with a small dose of MAP
causes ulcerative colitis, while infection with a large dose
of MAP causes Crohn’s disease
At the microscopic level, a “small number” of organisms
means 1 or 2 microorganisms within a single cell,
requiring x1000 magnification to be seen under the light
microscope [60], while a “large number” of organisms
means a group of 3 or more organisms within a single
cell, that can be identified at a magnification of x400
[72]. At the macroscopic level, however, a small number
of organisms, a small “bacterial burden” or a small
“dose” of MAP refers to numbers of organisms on the
order of 10
7, 10 million organisms or less, while a large
bacterial burden refers to doses on the order of 10
8 or
100 million organisms or more.
In a recent study, Smith and colleagues [73] demon-
s t r a t e dt h a tp a t i e n t sw i t hC r o h n ’sd i s e a s eh a v et r o u b l e
clearing large numbers of subcutaneously injected
Escherichia coli organisms from their tissues:
Bacterial clearance was dramatically different
between the two (HC or healthy control and CD or
Crohn’s disease) groups. In HC subjects, clearance
rates were relatively stable between 10
5 and 3 × 10
7
organisms and actually increased at the highest dose,
whereas in CD, although it was normal at 10
5 and
10
6, there was a dramatic and highly significant drop
in clearance at and above 10
7 bacteria [73].
These researchers concluded that Crohn’s patients can
clear small doses of bacteria from their tissues, but not
large doses:
Most acute infections originate from a small number
of inoculating organisms, which even the dampened
immunity in CD appears able to control. Our find-
ings of the relationship between bacterial dose and
clearance are important in this respect because they
demonstrate that CD patients can deal efficiently
with small numbers of organisms in the tissues, but
that the clearance mechanisms are overwhelmed by
a large bolus of bacteria [73].
These researchers discuss the idea that the ileum and
proximal colon are exposed to large numbers of luminal
bacteria, specifically in the range of 10
8 in the ileum and
10
11 in the colon, and speculate that Crohn’sp a t i e n t s
might have trouble handling these massive doses of nor-
mal luminal bacteria [73]. However, an alternative expla-
nation is that patients with Crohn’s disease do not have
trouble handling massive loads of normal luminal bac-
teria, but do have trouble handling large doses of MAP.
M A Pi so n eo ft h es u b s p e c i e so ft h eMycobacterium
avium complex (MAC) group of microorganisms [74].
Normal water treatment processes such as filtration and
chlorination amplify rather than eliminate MAC organ-
isms by killing off their competitors [75,76]. In addition,
MAC organisms grow on tap water pipes [77], in bio-
films [78] and on plastic water bottles [79]. MAP has
been identified in drinking water in the United States
[80,81] and elsewhere [82]. It is estimated that MAC
organisms may be present in drinking water on the level
of up to 700,000 or 7 × 10
5 organisms per liter of water
[77]. If an individual drinks 2 liters of water a day, it
will take just over 2 months to ingest 10
8 or “massive
numbers” of MAP organisms.
Once the level of MAP organisms in drinking water
regularly reaches hundreds of thousands of organisms
per liter, the chances of ingesting such large doses of
MAP reaches a saturation level [43] and the rate of
Crohn’s disease and ulcerative colitis in a population
stabilizes, with the chances of ingesting large doses of
MAP generally being greater than ingesting small doses.
Therefore, in populations with a high prevalence of IBD,
there is usually a higher prevalence of Crohn’s disease
than ulcerative colitis [67,83-85].
As discussed above, when infected with a small dose of
MAP, an adult develops ulcerative colitis relatively soon
after infection, while a child develops Crohn’s disease
many years after infection. As the level of MAP organ-
isms increases in the environment, including drinking
water, a child has a greater chance of getting infected
with a large dose. The author proposes that children
infected with a large dose of MAP develop Crohn’sd i s -
ease with a shorter latency period between infection and
clinical disease, including newborn infants [86].
In the study above [73], ulcerative colitis patients were
able to clear large doses of E. coli,u n l i k et h eC r o h n ’s
patients. The author believes that ulcerative colitis
patients have a more aggressive response to any dose of
MAP, whether small or large, whereas Crohn’sp a t i e n t s
can handle small doses of MAP but not large ones. So
patients develop ulcerative colitis even when infected
with small doses of MAP.
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MAP is excreted in an infected animal’s feces and
secreted in its milk. There are, therefore, 2 different
routes of infecting humans with MAP: fecal-oral trans-
mission via contaminated water, and consumption of
contaminated milk or products made from contami-
nated milk. A careful examination of the literature
reveals that routes of infection that result in concentrat-
ing MAP result in a greater likelihood of developing
Crohn’s disease rather than ulcerative colitis.
The first route of transmission of MAP to humans is
fecal-oral transmission. “Fecal-oral spread is an impor-
tant means of transmission of a variety of bacterial, viral
and parasitic diseases...It may involve...finger-to-mouth
spread, the use of night soil as fertilizer, or fecal con-
tamination of food or water” [19]. The reported clusters
of Crohn’s disease associated with fecal-oral transmis-
sion have involved the use of manure as fertilizer
[21,87] and possible fecal contamination of treated (tap)
water [88], untreated (well) water [89] and surface water
used for recreation [20]. Direct contact with dairy cattle
feces has also been associated with an increased risk of
ulcerative colitis in adult male farm workers [90].
MAP causes chronic intestinal disease in animals
whether ingested, injected subcutaneously or intrave-
nously, or inhaled [7], and aerosolization from possibly
MAP-contaminated bodies of water, particularly rivers, is
associated with an increased risk of Crohn’sd i s e a s ea s
compared to ulcerative colitis. There is a particularly
high incidence of Crohn’s disease in cities with rivers
running through them, as exemplified by the author’s
home of Spokane, Washington, in the United States [91]
and Cardiff, in the United Kingdom [85,92-94]. In Car-
diff, the high-incidence Crohn’s disease “wards” are adja-
cent to the river in a pattern exactly downwind of the
prevailing wind pattern, in contrast to ulcerative colitis
cases that are spread throughout the city’s wards [94-96].
The author believes that the MAP organism is concen-
trated in the aerosolized water bubbles, and it is this con-
centration of MAP bacteria to large numbers by the
aerosolization process [97] that results in Crohn’s disease
rather than ulcerative colitis in infected patients.
The second route of MAP transmission to humans is
through contaminated milk. Despite the concerted study
of the possible transmission of MAP to humans from
pasteurized milk [98,99], the reported clusters of
Crohn’s disease suggest that it is unpasteurized or raw
milk or milk products that carry the greater risk of
infection. The author believes that the potentially large
numbers of MAP in raw milk [21] and cheese [87] are
the cause of the associated clusters of Crohn’s disease;
whereas the logarithmically smaller number of MAP
organisms [100] in pasteurized milk [101] might trigger
ulcerative colitis [102,103].
Finally, the literature suggests that MAP in milk is
more invasive than MAP in water, because of the organ-
ism’s passage through mammary gland epithelial cells
and because of the hyperosmolar nature of milk [104].
The author speculates that the association between
sugary cereals and an increased risk of Crohn’s disease
[105-107] and ulcerative colitis [108,109] may be a result
of the increase in osmolarity of the milk caused by the
sugar in the cereal, and decreasing the osmolarity of
fluid in the digestive tract by carbohydrate-restricted
diets [110,111] may be the cause of their reported effi-
cacy in treating both Crohn’s disease and ulcerative
colitis.
Crohn’s disease and ulcerative colitis are not genetic
diseases, but genetic polymorphisms related to the
processing of intracellular bacteria, and specifically
mycobacteria increase the risk of developing Crohn’sd i s e a s e
rather than ulcerative colitis, when infected with MAP
Previous authors have suggested that ulcerative colitis
and Crohn’s disease have the same etiology, with
Crohn’s disease patients having more of the predispos-
ing genes than ulcerative colitis patients:
Crohn’s disease and ulcerative colitis may be the
same disease with similar causes and with a quanti-
tatively related genetic basis. Crohn’sd i s e a s ew o u l d
be the result in people with a large concentration of
genes, while fewer of the relevant genes would result
in ulcerative colitis [112].
The accumulation of genetic polymorphisms asso-
ciated with an increased risk of developing Crohn’sd i s -
ease as compared to ulcerative colitis supports this
contention. The NOD2/CARD15 protein is an intracel-
lular pattern recognition receptor that appears to not
only recognize intracellular bacteria in general, but bac-
teria from the genus Mycobacteriae, including M. leprae
[113,114] and MAP [115]. The ATG16L1 and IRGM
proteins are involved in the process of autophagy, which
is one of the ways cells process and eliminate intracellu-
lar bacteria [116]. The NRAMP (natural resistance asso-
ciated macrophage protein) 1 gene [117] is associated
with an increased risk of developing Johne’sd i s e a s ei n
sheep [118] as well as Crohn’s disease [117], leprosy
[119] and pulmonary MAC infections [120]. The
NRAMP protein is expressed in reticuloendothelial cells
[121], a possible location of the MAP organism in
humans with Crohn’s disease [122]. Individuals with one
or more of these genetic polymorphisms, all of which
make it slightly more difficult for individuals to process
intracellular bacteria, haveas l i g h t e rg r e a t e rc h a n c eo f
developing Crohn’s disease rather than ulcerative colitis,
when infected with MAP.
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however, develop Crohn’s or ulcerative colitis in any sig-
nificant numbers. Infection with MAP causes Crohn’s
disease and ulcerative colitis independently of having
these polymorphisms. “In other words, regardless of
whether you carry the mutant allele or not, M. avium
paratuberculosis infection has the same tendency to pro-
duce CD” [123]. Depending on the country and region,
these genetic polymorphisms are not associated with
Crohn’s disease [68,124].
The influence of sex: boys develop Crohn’s disease more
easily than girls, while men develop ulcerative colitis and
women develop Crohn’s disease, when infected with MAP
It is commonly known that infant males are more prone
to infectious diseases than infant females, probably due
to weaker immune systems [125]. This weaker immune
response might cause boys to develop Crohn’s disease
more often than ulcerative colitis [67,126-128] when
infected with MAP, because they probably have a
weaker immune response to the MAP organism. It has
been postulated that Crohn’s disease is not an autoim-
mune disease, a disease of excessive or over reactive
immunity, but an immune deficiency disease [129]. Indi-
viduals with Crohn’s disease have a less active response
to the MAP organism, in contrast with individuals with
ulcerative colitis, who have a more active response, as
proposed above.
In contrast to children, adult females seem slightly
but consistently more likely to develop Crohn’sd i s e a s e
[64,130] and adult males to develop ulcerative colitis
when infected with MAP. While purely speculative,
this difference might be due to the differing effects of
testosterone [131] versus estrogen [132] on blood and
lymphatic vessels, to the greater effects of smoking on
females than males [133], or to the increase in oral
contraceptive use, with its known vascular complica-
tions [134].
Smoking increases the risk of both ulcerative colitis and
Crohn’s disease, but nicotine has different effects on
colonic versus small bowel inflammation
There are two commonly accepted beliefs about the
relationship between smoking and Crohn’s disease and
ulcerative colitis: smoking increases the risk of Crohn’s
disease but protects an individual from developing
ulcerative colitis, and smoking increases the severity of
Crohn’s disease, but decreases the severity of ulcerative
colitis. If ulcerative colitis and Crohn’s disease are both
caused by MAP, how can these apparently dichotomous
effects be explained? An excellent review article by
Lakatos and colleagues [135] helps elucidate the reasons
for the different effects of smoking on these diseases.
First, in children, smoking increases the risk of devel-
oping both ulcerative colitis and Crohn’sd i s e a s e .I na
study of inflammatory bowel disease in Kentucky chil-
dren [126], children who started smoking before
10 years of age were 7 times more likely to develop
ulcerative colitis than nonsmokers, and over 3 times
more likely to develop Crohn’s disease than nonsmo-
kers. If they started smoking before age 15, they were
over three times more likely to develop both diseases.
Smoking increased the risk of developing both Crohn’s
disease and ulcerative colitis, and in this one study
increased the risk of ulcerative colitis (7 times greater
risk) more than it increased the risk of Crohn’sd i s e a s e
(‘only’ 3 times greater risk).
Secondly, the literature commonly cites the statistic
that ulcerative colitis occurs in nonsmokers and ex-
smokers, but again a careful examination reveals that
smoking does not protect someone from developing
ulcerative colitis; it causes them to develop Crohn’s dis-
ease instead. Bridger and colleagues [136] demonstrated
that in siblings, smokers develop Crohn’s disease while
nonsmokers develop ulcerative colitis. They write:
We have shown...that in some cases smoking can
probably displace the phenotype of chronic IBD
from UC to CD...The explanation of the apparent
“protective” effect of smoking on sporadic UC may
be that the form of IBD that develops in a propor-
tion of smokers is not UC but CD [136].
Not only does smoking predispose a MAP-infected
individual to develop Crohn’s disease rather than ulcera-
tive colitis, it favors the development of small bowel dis-
ease [137], due to the effect of nicotine on reducing
colonic inflammation as discussed below.
The idea that smoking predisposes an individual
infected with MAP to develop Crohn’s disease rather
than ulcerative colitis is supported by the high preva-
lence of ulcerative colitis in members of the Mormon
Church, “where smoking is strongly discouraged” [135].
In a study of Mormons in Britain and Ireland, ulcerative
colitis was five times more common in Mormons than
in the general population [138] while the prevalence of
Crohn’s disease was the same. In comparative studies of
Hindus and Muslims in the United Kingdom
[68,139-141], Hindus (more likely to be nonsmokers)
had high rates of ulcerative colitis compared to Muslims
(more likely to be smokers); not smoking switched the
phenotype from Crohn’s disease to ulcerative colitis.
The lack of smoking did not protect nonsmoking popu-
lations from developing ulcerative colitis but instead
caused them to have higher rates of ulcerative colitis
compared to populations who smoked, keeping the
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usual ulcerative colitis/Crohn’s disease ratio.
But smokers with ulcerative colitis do have a more
benign clinical course than nonsmokers. If MAP causes
ulcerative colitis, what in the smoke is good for ulcera-
tive colitis? It is the nicotine in the smoke that helps
both colonic Crohn’s disease and ulcerative colitis. First,
nicotine reduces tone and muscular activity in the
colon; it slows the colon down [142]. Secondly, nicotine
increases small bowel inflammation but decreases colo-
nic inflammation [143,144]. Transdermal nicotine
patches help both ulcerative colitis patients and patients
with colonic Crohn’s disease [145].
So the superficial paradox of the effects of smoking on
Crohn’s disease and ulcerative colitis is rather easily
explained. Smoking increases the risk of both diseases,
and increases the risk that the clinical expression of
MAP infection will be Crohn’s disease rather than
ulcerative colitis.
Conclusion: hope for the prevention and cure of the no
longer idiopathic inflammatory bowel diseases
It is likely that MAP is the cause of a range of human
gastrointestinal diseases including irritable bowel syn-
drome [146,147] as well as ulcerative colitis and
Crohn’s disease. MAP has also been investigated in the
pathogenesis of other so-called autoimmune diseases
including sarcoidosis [148,149], type-1 diabetes
[150-152] and Hashimoto’s thyroiditis [153]. If we
accept that both ulcerative colitis and Crohn’s disease
are caused by a specific infectious microorganism,
MAP, a long overdue transformation will take place in
the prevention and treatment of these diseases. A
rapid, focused effort to determine and implement the
most efficacious treatments of already infected indivi-
duals [110,111,154-158], and methods of preventing
initial infection by vaccination [159] and the effective
removal of MAP organisms from drinking water [160]
will become top priorities. We can end the “public
health tragedy” [161] of Crohn’sd i s e a s e ,a n du l c e r a t i v e
colitis, in our lifetimes.
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